Business Context and Reporting Period
Company: Nkarta, Inc. (NKTX)
Filing Type: Form 10-K (Annual Report)
Period Covered: Fiscal year ended December 31, 2025
Business Overview: Nkarta is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company's lead product candidate, NKX019, targets the CD19 antigen for the treatment of B-cell mediated autoimmune diseases. The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(104.1) million | $(108.8) million |
| Operating Expenses | $122.0 million | $128.2 million |
| Research & Development (R&D) | $90.4 million | $96.7 million |
| General & Administrative (G&A) | $31.6 million | $31.5 million |
| Interest Income | $15.5 million | $19.3 million |
| Cash, Cash Equivalents, and Investments | $295.1 million | $377.2 million |
| Accumulated Deficit | $(648.3) million | $(544.2) million |
| Net Cash Used in Operating Activities | $(88.7) million | $(99.7) million |
Note: All figures in millions unless otherwise noted. The filing text does not provide specific gross margin or operating margin data as the company has no revenue.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $4.7 million (4.3%) year-over-year, primarily driven by a $6.3 million decrease in R&D expenses and a $3.8 million decrease in interest income.
- R&D Expense Decrease: R&D expenses declined due to a $9.3 million reduction in personnel costs following a workforce reduction in March 2025. This was partially offset by increased clinical spending for the NKX019 autoimmune program.
- G&A Expense Increase: G&A expenses increased slightly by $0.1 million, driven by $4.9 million in severance expenses and $0.8 million in right-of-use asset impairment, offset by lower personnel and facility costs.
- Workforce Reduction: In March 2025, the company executed a reduction in force affecting 53 positions (approximately 34% of the workforce) to streamline operations and reduce costs.
- Asset Impairment: The company recorded an impairment charge of $0.8 million related to right-of-use assets in 2025 due to a sustained decline in stock price and market capitalization falling below net asset value.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: As of December 31, 2025, the company held $295.1 million in cash, cash equivalents, and investments. Management believes these resources are sufficient to fund operations for at least 12 months following the filing date.
- Clinical Progress: In November 2025, the company announced deep B-cell depletion in patients treated with NKX019 using a modified lymphodepleting conditioning regimen (Fludarabine and Cyclophosphamide). Enrollment in the second dose-escalation cohort was authorized.
- Pipeline Focus: The company has deprioritized its oncology programs (NKX019 for B-cell malignancies and NKX101) to focus resources on NKX019 for autoimmune diseases (Lupus Nephritis, Primary Membranous Nephropathy, Scleroderma, Myositis, and AAV).
Risks and Contingencies
- Capital Requirements: The company expects to continue incurring significant losses and will require additional capital to advance clinical trials and commercialization. Future financing may result in dilution to stockholders.
- Clinical Uncertainty: There is no guarantee that NKX019 will demonstrate efficacy or safety in later-stage trials. Enrollment challenges remain a significant risk due to competition for patients and sites.
- Manufacturing Risks: The company relies on a sole supplier (Miltenyi) for certain critical manufacturing steps and reagents. Disruptions in supply could delay clinical trials.
- Intellectual Property: The company relies on licensed technology from the National University of Singapore and St. Jude Children's Research Hospital. Termination of this license could impede development.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $295.1 million cash balance against the projected burn rate, considering the company's history of significant losses and the need for future capital raises.
- Clinical Trial Data: Review the full data release regarding the "deep B-cell depletion" observed in November 2025 to assess the clinical validity of the modified lymphodepleting regimen.
- Workforce Impact: Assess the long-term impact of the 34% workforce reduction on the company's ability to execute its clinical development plan and manage its manufacturing facilities.
- Supply Chain Dependencies: Investigate the risks associated with the sole supplier relationship for the Miltenyi CliniMACS Plus system and the short expiration periods of related reagents.
- Asset Impairment: Monitor for potential future impairment charges given the company's market capitalization is currently below its net asset value.